HAIFA, Israel – June 6 , 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company), a leading biotechnology company that transforms cells into solutions, today announced the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has exercised its option for year two of the three-year $4.2 million contract it entered into with Pluri in July 2023. During the 12 months from July 1, 2024 through June 30, 2025, the NIAID will provide $1.4 million for the Company to manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
H-ARS is caused by exposure to life-threatening amounts of ionizing radiation, such as that which may occur during a radiological or nuclear accident, terrorist activities, and/or warfare. The condition is characterized by dose-dependent bone marrow depression, leading to neutropenia, thrombocytopenia, and anemia, and possibly death. The U.S. Food and Drug Administration (FDA) previously approved an Investigational New Drug application for PLX-R18 for the treatment of H-ARS in the case of nuclear or radiological or incidents and granted it Orphan Drug Designation.
Over the past year, Pluri has collaborated with the U.S. Department of Defense’s (DoD) Armed Forces Radiobiology Research Institute at the Uniformed Services University of Health Sciences in Bethesda, Maryland, resulting in significant advancements in the development of PLX-R18 as a potential treatment for H-ARS.
“PLX-R18 is being developed as a next-generation countermeasure against the damage caused by ionizing radiation, aiming to treat single-agent neutropenia, thrombocytopenia, and anemia. We would like to thank NIAID for its trust and for choosing to exercise its second-year option, this action validates the potential of PLX-R18 to treat H-ARS,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “We are pleased to continue working with the NIH and the DoD’s Armed Forces Radiobiology Research Institute, to advance this potential treatment for a truly devastating medical condition, especially in light of recent geopolitical events and the global threat of nuclear disasters.”
PLX-R18 has been safely tested in both humans and animals. Prior studies funded by the NIH/NIAID and conducted in accordance with the FDA’s Animal Rule pathway demonstrated that PLX-R18 administered to animals after radiation exposure for H-ARS significantly increased survival rates from 29% in the control group to 97% in the treated group (p<0.001). Studies conducted by the DoD have shown that PLX- R18, administered as a prophylactic measure 24 hours before radiation exposure, and again 72 hours after exposure, resulted in a significant increase in survival rates, from 4% survival in the placebo group to 74% in the treated group (log-rank test p< 0.0001). In addition, the data show a significant increase in recovery of white blood cell (p = 0.0047), platelet (p = 0.0070), neutrophil (p = 0.0003) and lymphocyte (p = 0.0025) counts compared to administration of vehicle, and also demonstrate a favorable safety profile.
PLX-R18 was tested in humans with incomplete hematopoietic recovery following hematopoietic cell transplantation and was well tolerated with a favorable safety profile. Patients treated with PLX-R18 showed an increase in all three blood cell types compared to the baseline with platelet (p<0.001), hemoglobin (p=0.02) and neutrophil (p=0.15) levels increasing as early as 1 month following PLX-R18 administration and enduring up to 12 months following treatment, while experiencing a significant reduction in mean number of transfused units from a monthly 5.09 to 0.55 for platelets (p=0.045) and 2.91 to 0 for red blood cells (p=0.0005) over 12 months of follow-up.
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for
commercial use and is pioneering a biotech revolution that promotes global well-being and
sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers Contract Development and Manufacturing Organization (CDMO) services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential benefits to be derived from the use of PLX-R18; its collaborations with strategic partners; its regulatory strategy; and that work during the contract period is expected to make further progress toward marketing approval for PLX-R18 as a medical countermeasure for exposure to nuclear radiation and lead to PLX-R18 becoming eligible for purchase by the U.S. Strategic National Stockpile. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – May 20, 2024 – Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today announced a strategic collaboration with Wilk Technologies Ltd. (TASE: WILK) (“Wilk Technologies” or “Wilk”), a developer of authentic, cell-cultured human and animal milk components. By combining Pluri’s cutting-edge 3D cell-expansion technology with Wilk’s expertise in developing cultured human breast and animal milk products, the strategic collaboration will use the components of breast milk to develop a unique medical food intended for the elderly on a commercial scale.
Medical foods for the elderly are specifically formulated and designed to meet the unique nutritional needs and health concerns of older adults. Demand for medical food products is growing, driven by the growing geriatric population and increasing prevalence of chronic illnesses impacting adults who may have nutritional deficiencies stemming from their illness or its related treatment.
“Wilk Technologies is committed to unlocking the potential of cell-based medical foods,” said Avital Beck, Ph.D., CEO of Wilk Technologies. “This collaboration presents an opportunity to leverage Pluri’s 3D cell expansion technology with Wilk’s unique cell lines. The collaboration aims to develop and scale Wilk’s innovative products to commercial readiness, potentially leading to powerful medical food for the elderly.”
“At Pluri, our mission is to leverage cell-based technology to tackle humanity’s most pressing issues, like age-related health decline and global food insecurity,” said Yaky Yanay, CEO and President of Pluri. “This collaboration with Wilk Technologies perfectly aligns with our vision as we harness the unique properties of breast milk cells to create medical food solutions for a rapidly growing elderly population. We’re thrilled about the potential of this collaboration to improve the quality of life for millions and revolutionize senior health on a global scale.”
About Pluri Inc.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and
sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
About Wilk Technologies Ltd.
Wilk is dedicated to revolutionizing the dairy and infant formula industry by enabling the sustainable production of high-value dairy products using the lowest carbon footprint. Leveraging over 10 years of industry-leading research, Wilk is focused on two main development tracks: cultured human breast milk ingredients and cultured cow milk ingredients. Wilk produces its solutions for various purposes: enriching infant formula with cultured breastmilk ingredients for babies, alternative dairy healthy diets, and the extrapolation of milk’s nutritional components for the pharma industry. Last year, Wilk Technologies received investments from Danone, Steakholder Foods, & Coca Cola Israel.
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expected strategic collaboration, the potential to lead to powerful medical food for the elderly and the potential benefits of the collaboration. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – May 2, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective treatments.
Leveraging two decades of cell expansion expertise and its proprietary technology, Pluri recently unveiled a novel method for expansion of immune cells as well as a new U.S. granted patent. Pluri believes that the newly announced immunotherapy platform can revolutionize solid tumor treatment and unlock the potential of placental MAIT cells, which are unique immune cells derived from healthy donors.
The Company also announced that Dr. Prasad S. Adusumilli (Min H. and Yu-Fan C. Kao Chair in Thoracic Cancers at Memorial Sloan Kettering Cancer Center) and Dr. Richard L. Kendall (Former Head of Oncology Research at Amgen), two renowned oncology researchers, joined its newly formed Scientific Advisory Board to provide strategic counsel as this project advances.
Offering substantial potential benefits compared to conventional T cells, Pluri’s MAIT cells are isolated from the human placenta, a source rich in highly potent allogeneic immune cells. These cells are potent effector cells, potentially targeting tumors through multiple mechanisms while expressing high levels of various chemokine receptors, which facilitate their migration directly to tumor sites. Furthermore, unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing Graft versus Host Disease (GvHD) – a significant advantage over other potential allogeneic products – but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy.
When combined with Pluri’s 3D cell expansion technology, the MAIT platform will enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, off-the-shelf therapy for cancer patients.
“Our MAIT platform is a culmination of two decades of innovation and scientific expertise, paving the way for a new era of effective immunotherapy,” said Yaky Yanay, CEO and President of Pluri. “We believe that our MAIT cells can make targeted, affordable and effective treatments readily accessible to all who need them. Our commitment extends beyond mere technological advancement; we aim to redefine what’s possible in the fight against cancer.”
“Despite revolutionary progress in hematological malignancies, an equivalent success has yet to be duplicated in solid tumor malignancies, which present unique challenges. Pluri’s MAIT cells exhibit inherent biological advantages that may be pivotal in developing effective treatments for tough-to-treat cancers and solid tumors in particular,” said Dr. Arthur Machlenkin, PhD, Chief Scientific Officer of Pluri. “We are excited to continue developing these powerful cells into transformative therapies.”
The global cancer immunotherapy market was valued at $100 billion in 2022 and expected to surpass around $275.11 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 10.70% from 2023 to 2032.
Understanding the potential of Pluri’s MAIT cells, two internationally recognized oncology researchers joined Pluri’s Scientific Advisory Board (SAB): Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall.
Dr. Adusumilli, MD, is Professor and Deputy Chief, Thoracic Service; Vice Chair for Translational Research, Dept. of Surgery; Director, Mesothelioma Program; Min H. and Yu-Fan C. Kao Chair in Thoracic Cancers at Memorial Sloan Kettering Cancer Center (New York, NY). Research led by Dr. Adusumilli has focused on regional immunotherapy strategies, resulting in translation of mesothelin-targeted CAR T-cell immunotherapy for malignant pleural mesothelioma, lung, and breast cancers.
“I am excited to work with Pluri to develop scalable, engineered immune cells for cancer immunotherapy,” said Dr. Prasad S. Adusumilli. “The cells’ intrinsic ability to migrate to tumor sites can offer a beacon of hope in the fight against solid tumors, a significant unmet medical need.”
Dr. Kendall, Ph.D, is Chief Science Officer of Catena Bio, a company whose technology enables them to synthesize novel biomolecules in any structure, combination, or orientation. Previously, Dr. Kendall was the President and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Notably, Dr. Kendall also held significant positions at leading biopharmaceutical companies, serving as Vice President of Research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies, as well as Executive Director and Head of Oncology Research at Amgen.
“By combining advanced cell expansion technology with the unique attributes of MAIT cells, Pluri is on the brink of delivering off-the-shelf solutions with unmatched consistency,” Said Dr. Richard L. Kendall.
Pluri™ is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its technology and the placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors, the potential of the MAIT cells and its characteristics and benefits in comparison to conventional T cells, the belief that the newly announced immunotherapy platform can revolutionize solid tumor treatment and unlock the potential of placental MAIT cells, the MAIT cells’ advantage over other potential allogeneic products, Pluri’s belief that the MAIT platform will enable commercial scale production of powerful immune cells as a potential first-in-class, ready to use, off-the-shelf therapy for cancer patients and the belief that the MAIT cells can make targeted, affordable and effective treatments readily accessible to all who need them. . These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – Apr. 8, 2024 – Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, “System and Methods for Immune Cells Expansion and Activation in Large Scale.”
Pluri’s novel technology represents a paradigm shift in immune cell expansion methodologies because, unlike traditional approaches, its method employs a fundamentally different concept. Pluri’s proprietary 3D cell expansion technology mimics the natural lymph node like environment that immune cells have within the human body. The tightly controlled and fully automated bioreactor system provides cells with the conditions they need in order to expand, enabling efficient expansion of immune cells at scale and quality. This innovative approach ensures that the produced immune cells retain their integrity, functionality, and therapeutic efficacy, thus offering a promising solution to meet the escalating demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases.
Pluri’s patented technology marks an important milestone in the field of allogeneic cell therapy, positioning the Company at the forefront of innovation. By addressing the critical challenges faced by current allogeneic cell therapies, such as limited donor cell availability and scalability issues, Pluri’s technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success. With a commitment to pushing the boundaries of possibility, Pluri is poised to lead the charge towards realizing the full potential of allogeneic cell therapy, ultimately transforming the lives of patients worldwide.
“We believe that our continued investment in technology, paired with two decades of expertise, enable us to develop the next generation of medical treatments,” said Yaky Yanay, CEO and President of Pluri. “Pluri’s patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies. By harnessing the power of our proprietary technology, we are not only advancing the possibilities of allogeneic cell therapy, we are also reaffirming our commitment to improving patient outcomes worldwide.”
The patented technology addresses the global immune cell engineering market size which is expected to reach $11.66 billion by 2030, from $2.82 billion in 2023, at a CAGR of 22.5% during the forecast period.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, foodtech and agtech. The Company also offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell- based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential of its technology, that its technology can potentially open doors to vast opportunities for therapeutic advancement and commercial success, the belief that its continued investment in technology, paired with two decades of expertise, enable it to develop the next generation of medical treatments, that its patented technology represents a significant leap forward in the field of immune cell expansion, addressing the growing global demand for advanced cell-based therapies, and the expected growth in the allogeneic cell therapy market.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know- how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries
HAIFA, Israel, March 28, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced leadership from its business verticals will be presenting at, and participating in, the following conferences:
Conference: MIW, Germany-Israel Technology
Date: April 10, 2024 Location: Berlin
Ms. Michal Ogolnik, leader of Pluri’s cell-based coffee business, will be presenting at MIW.
Pluri’s Chief Executive Officer & President, Yaky Yanay, will also attend.
Pluri’s cell-based coffee business is part of its PluriAgtech business vertical, which deploys its world-leading 3D cell expansion technology platform to reshape the agricultural landscape and redefine the possibilities of sustainable crop production.
Pluri’s patented coffee cell technology uses the Company’s breakthrough 3D cell expansion technology for mass-scale coffee plant cell cultivation. The Company is leveraging two decades of experience and know-how in cell manufacturing to drive the future of coffee science.
By utilizing its eco-efficient mass scale production methods, Pluri offers reduced carbon footprint through cultivation, lowering resources while increasing yield for one of the world’s most traded food commodities.
Conference: ATiO Conference 2024
Date: April 10-12, 2024 Location: Berlin
Pluri’s Chief Executive Officer & President Yaky Yanay will participate in a panel of discussions and Chief Business Development Officer of Pharma Efrat Kaduri will attend the event.
Advanced Therapies in Orthopedics Foundation (ATiO) is an international specialist society founded as a non-profit association. The event is dedicated to new perspectives and possibilities in the field of advanced therapies in orthopedics and will include a discussion between key opinion leaders in research, clinics, finance and corporate.
Pluri’s cell therapy product, PLX-PAD, will be evaluated as potential treatment for knee osteoarthritis (OA) as a part of the PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis) collaboration led by Charité Berlin and supported by the EU Horizon Europe program. PLX-PAD is a multifactorial therapy product candidate with robust clinical data. It demonstrated increased muscle strength in two clinical studies and is believed to induce systemic anti-inflammatory effect and to reduce post-operative oxidative stress.
Conference: Biomed Israel
Date: May 21-23, 2024
Location: Tel Aviv
Pluri’s leadership will attend the event.
Conference: Bio International Convention
Date: June 3-6, 2024 Location: San Diego
Recently launched in January of 2024, PluriCDMO helps innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector by offering manufacturing support from the preclinical and development stages to late stage clinical and commercial production, including fill and finish and logistics.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond.
Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses its potential future service agreements, the potential benefits of its technology and that its cell therapy product, PLX-PAD, will be evaluated as a treatment for knee osteoarthritis.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward- looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – March [27], 2024 – Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company that transforms cells into solutions, today announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share (the “Common Shares”) at a ratio of 1-for- 8 is expected to be implemented at market open on April 1, 2024.
The Company’s Common Shares will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on April 1, 2024, under the Company’s existing trading symbol “PLUR”, but will trade under a new CUSIP Number, 72942G203.
After giving effect to the reverse share split of the Company’s Common Shares, each eight (8) Common Shares will be combined into one Common Share, such that the Company’s 41,816,959 Common Shares outstanding will be reduced to approximately 5,227,120 Common Shares outstanding (the “Reverse Share Split”). In addition, the authorized capital shares of the Company are being reduced from 300,000,000 Common Shares to 37,500,000 Common Shares as a result of the Reverse Share Split and pursuant to Nevada Revised Statutes (NRS) Section 78.207. No fractional shares will be issued as a result of the reverse split as any fractional shares resulting from the reverse split will be rounded up to the nearest whole share on a per shareholder basis.
The Board of Directors of the Company approved the action in accordance with Nevada law (NRS Section 78.207). No additional Company or shareholder approval is required because both the number of authorized Common Shares and the number of outstanding Common Shares will be proportionally reduced as a result of the Reverse Share Split, the Reverse Share Split will not adversely affect any other class of shares of the Company and the Company will not pay money or issue scrip to shareholders who would otherwise be entitled to receive a fractional share as a result of the reverse split.
The reverse split will not impact any shareholder’s percentage ownership of Pluri or voting power, except for minimal effects resulting from the treatment of fractional shares.
All options, unvested shares of restricted stock, restricted stock units and warrants of the Company outstanding prior to the split will be appropriately adjusted.
Equiniti Trust Company, LLC, will act as the exchange agent for the reverse split. Please contact Equiniti Trust Company, LLC for further information at (718) 921-8200.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability.
The Company’s technology platform, a patented and validated state-of- the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the implementation of the reverse share split.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
HAIFA, Israel – March 21, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today addressed the price volatility challenge detailed in the International Coffee Organization’s (ICO) 2024 Market Report (the “Report”) According to the Report, one of the factors creating price volatility is the erratic weather conditions across the globe; from frost in Brazil in 2021 to the El Niño phenomenon expected to worsen heatwaves in Vietnam in 2024. Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.
Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions. Pluri recently announced the launch of its cell-based coffee, its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry. The Company’s cell production method grows coffee quickly and reliably in an environmentally sustainable, cost- effective, tightly controlled fully automated manufacturing process that is highly scalable. Pluri’s cell-based coffee is estimated to slash water usage by 98% throughout the entire supply chain and reduce farmland usage by 95% as compared to traditional growing methods.
To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.
“Pluri’s proprietary method for producing coffee aims to produce a better product with regards to taste, texture, scent, and sustainability,” stated Pluri’s CEO and President Yaky Yanay. “Our solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability, price stability and saving everyone’s favorite beverage.”
Learn more about Pluri’s innovative cell-based coffee technology by visiting our website.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of challenges— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech, agtech and biologics and offers CDMO services. Pluri establishes partnerships that leverage the Company’s proprietary 3D cell-based technology across various industries that require effective, mass cell production.
To learn more, visit us at www.pluri-biotech.com or follow Pluri on LinkedIn and X (formerly known as Twitter).
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses the potential benefits of its cell- based coffee and that its solution can help the industry produce coffee in a stable and controlled environment, ensuring consistent availability and price stability.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Jessica Daitch at Jessica@quantum-corp.com / Madeline Weirman at Maddie@quantum-corp.com
HAIFA, Israel – March 19, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.
Conference: Bio-Europe Spring Date: March 18-20, 2024 Location: Barcelona
Pluri’s Chief Business Development Officer-Pharma Efrat Kaduri will attend the event.
BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.
Conference: Advanced Therapies 2024
Date: March 19-20, 2024 Location: London
Pluri’s Chief Technology Officer Lior Raviv will participate in a panel discussion titled: Points to consider when building supply chain operations from scratch on Tuesday, March 19, 2024 at 1:40 PM.
He will also give a presentation titled: Unleashing the Allogeneic Potential by Using Large Scale Automated Manufacturing Platforms on Wednesday, March 20, 2024 at 2:40 PM.
Pluri’s Chief Commercial Officer PluriCDMO Andy Lewin will attend the event.
The Advanced Therapies congress is Europe’s largest cell and gene therapy conference and exhibition. The event brings together the world leaders in advanced therapy medicinal product development and the most senior executives in charge of the latest tech and strategies that are driving the industry forward.
Conference: CISH Impact Investments Holdings Conference
Date: March 28, 2024 Location: Online Event
Pluri’s Chief Executive Officer & President Yaky Yanay will be presenting at the conference on Thursday, March 28, 2024 at 2:20 PM.
CISH Impact Investments Holdings Conference is a global event on impact opportunities and investments in promising technology companies that have a positive impact on the community and the environment.
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com/ Jessica Daitch at Jessica@quantum-corp.com
PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
HAIFA, Israel – March 14, 2024 – Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell- free therapeutics for complex fibrotic conditions.
PluriCDMO™ will support Remedy Cell’s production team in the manufacturing of a clinical- grade Working Cell Bank (WCB) and GMP batches of Remedy Cell’s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Remedy Cell CEO, Ayelet Dilion-Mashiah, said, “This is an exciting time at Remedy Cell as we initiate the early stages of clinical development of our novel drug candidate, RC-0315, for IPF, a condition with significant unmet treatment needs. We look forward to the manufacture of our drug candidate at Pluri’s GMP facilities and believe that their vast experience developing and manufacturing cell therapies will accelerate our time to market.”
Pluri CEO and President, Yaky Yanay, said, ”Remedy Cell is an innovative company developing crucial treatments like RC-0315 to address complex conditions with limited therapeutic options. We are delighted that Remedy Cell has chosen PluriCDMO™ to assist with their clinical manufacturing, and we eagerly anticipate the establishment of a robust, long-term partnership grounded in excellence and collaboration.”
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
Pluri launched its CDMO division in January 2024, leveraging its proprietary knowledge, cutting- edge technology and cell therapy production facility on behalf of clients. PluriCDMO™ clients gain access to Pluri’s state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables 3D cell expansion at mass scale via a fully controlled, automated and validated process.
For more information visit www.pluri-biotech.com/cdmo or contact CDMO@Pluri- biotech.com
Remedy Cell Ltd., a biopharmaceutical company, harnesses scientific advancements in cell- derived therapies to develop first-in-class, breakthrough treatments for patients suffering from complex fibrotic diseases.
The company’s lead product RC-0315 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) has accomplished very encouraging pre-clinical results and it aims to reach first in human in early 2025. IPF is a serious chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs. IPF is an Orphan Disease that affects 100,000 patients in the US and approximately 110,000 patients in Europe.
There is currently no cure and IPF patients are not likely to survive beyond 2-5 years from diagnosis.
There is an urgent need for a therapeutic treatment option that effectively degrades fibrosis and restores lung function.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses that it anticipates the establishment of a robust, long-term partnership grounded in excellence and collaboration with Remedy Cell.
These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product
HAIFA, Israel – March 11, 2024 – In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or “the Company”) today announced an important expansion to its intellectual property portfolio with a new patent approval, that is designed to reshape the agricultural technology landscape. The patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” represents a major breakthrough in Pluri’s proprietary 3D bioreactor technology, enabling efficient cultivation of plant cells across various applications, from sustainable agriculture to critical healthcare solutions.
An immediate application for the patent is PluriAgtech’s sustainable cell-based coffee. The 3D cell expansion technology can produce high-quality coffee with 98% less water and 95% less growing area. Pluri’s patent and 3D cell expansion technology can also potentially address an emerging gap in agricultural healthcare, as approximately one-fifth of the 50,000 medical plants used today are on a list of threatened species.
The global cellular agriculture market was valued at $133 billion in 2021 and is projected to grow to $515 billion by 2030. This growth trajectory potentially positions Pluri’s newly patented technology as a potentially transformative force within this important industry. Yaky Yanay, Pluri’s Chief Executive Officer and President said: “This key patent not only solidifies our leadership in cell expansion technology but also aligns with our strategic vision to scale the production of cell-based products industrially, potentially opening a broad spectrum of market opportunities.”
With over 140 active and granted patents, Pluri’s robust IP portfolio is a testament to its pioneering role in the agtech industry. This patent, secured from the Israel Patent Office, further enhances Pluri’s competitive positioning through innovative contributions to sustainable agriculture and beyond.
“We believe this patent positions Pluri as a leader in cell expansion technology for the agtech industry.” stated Mr. Yanay. “PluriAgtech’s patented technology can be used for a wide range of plant cell products like food and beverages, medicine, ingredients and more. We see many opportunities in the agtech space, where Pluri is on the forefront of providing sustainable solutions for humanity’s greatest challenges both through our own proprietary products and in conjunction with potential partners.”
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability.
The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch.
Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services.
To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X.
This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws.
For example, Pluri is using forward-looking statements when it discusses its belief that its patent represents a major breakthrough in Pluri’s proprietary 3D bioreactor technology, the potential uses and benefits of its technologies and products, the growth projections for the global cellular agriculture market, that its newly patented technology is a potentially transformative force within its industry, its belief that cell expansion has the potential to become a major driver and future pillar of agtech, and the potential opportunities in the agtech space.. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.
Investors: investor.relations@pluri-biotech.com / Jennifer Zimmons at Jen@quantum-corp.com
Israel Media: Shachar Yental at Shacharye@gitam.co.il
U.S. Media: Madeline Weirman at Maddie@quantum-corp.com / Jessica Daitch at Jessica@quantum-corp.com
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.